Patents by Inventor Mohan Srinivasan
Mohan Srinivasan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11345752Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.Type: GrantFiled: February 28, 2019Date of Patent: May 31, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Nils Lonberg, Mohan Srinivasan
-
Patent number: 11242393Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.Type: GrantFiled: March 22, 2019Date of Patent: February 8, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Michelle Renee Kuhne, Alan J. Korman, Haichun Huang, Yiming Yin, Robert F. Graziano, Natalie A. Bezman, Pavel Strop, Richard Y. Huang, Guodong Chen, Mohan Srinivasan, Peter Sung Keun Lee, Gamze Ozlem Camdere
-
Publication number: 20220010301Abstract: Provided herein are functional interface mimics (FIMs), which mimic a functional interface of an interface protein. The FIMs comprise at least one peptide and at least one linking moiety, such as a linker or a cross-link. In some embodiments, the FIMs comprise at least two peptides connected by at least one linker. In some embodiments, the FIM is an immunogen. Also provided herein are methods of selected an FIM, and methods of producing an antibody using an FIM.Type: ApplicationFiled: November 13, 2019Publication date: January 13, 2022Inventors: Mohan SRINIVASAN, Matthew GREVING
-
Patent number: 11213586Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: GrantFiled: November 17, 2016Date of Patent: January 4, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Haichun Huang, Susan Chien-Szu Wong, Huiming Li, Bryan C. Barnhart, Aaron P. Yamniuk, Ming Lei, Liang Schweizer, Sandra V. Hatcher, Arvind Rajpal
-
Publication number: 20210395375Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.Type: ApplicationFiled: June 22, 2021Publication date: December 23, 2021Inventors: Josephine M. CARDARELLI, Alison WITTE, Mohan SRINIVASAN
-
Publication number: 20210324072Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.Type: ApplicationFiled: April 12, 2021Publication date: October 21, 2021Inventors: Mark F. Maurer, Tseng-hui Timothy CHEN, Brigitte DEVAUX, Mohan SRINIVASAN, Susan H. JULIEN, Paul O. SHEPPARD, Daniel F. ARDOUREL, Indrani CHAKRABORTY
-
Patent number: 11084881Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: GrantFiled: September 23, 2019Date of Patent: August 10, 2021Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
-
Patent number: 11072664Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.Type: GrantFiled: July 3, 2019Date of Patent: July 27, 2021Assignee: E.R. Squibb & Sons, L.L.C.Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
-
Publication number: 20210155703Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.Type: ApplicationFiled: April 3, 2019Publication date: May 27, 2021Inventors: Li-Sheng Lu, Mark J. Selby, Alan J. Korman, Shrikant Deshpande, Mohan Srinivasan, Jun Zhang, Haichun Huang, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova
-
Patent number: 11008390Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.Type: GrantFiled: December 20, 2018Date of Patent: May 18, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Mark F. Maurer, Tseng-hui Timothy Chen, Brigitte Devaux, Mohan Srinivasan, Susan H. Julien, Paul O. Sheppard, Daniel F. Ardourel, Indrani Chakraborty
-
Publication number: 20210011022Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.Type: ApplicationFiled: May 8, 2020Publication date: January 14, 2021Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Xi-Tao WANG, Olufemi A. ADELAKUN, Anne C. LEWIN, Alan J. KORMAN, Mark J. SELBY, Changyu WANG, Haichun HUANG, Karla A. HENNING, Nils LONBERG, Mohan SRINIVASAN, Michelle Minhua HAN, Guodong CHEN, Richard Y. HUANG, Indrani CHAKRABORTY, Susan Chien-Szu WONG, Huiming LI
-
Publication number: 20200399385Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: ApplicationFiled: April 13, 2020Publication date: December 24, 2020Applicant: Bristol-Myers Squibb CompanyInventors: Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Xiang SHAO, Mohan SRINIVASAN, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Patrick GUIRNALDA
-
Publication number: 20200299400Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.Type: ApplicationFiled: May 24, 2018Publication date: September 24, 2020Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
-
Publication number: 20200268901Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.Type: ApplicationFiled: April 15, 2020Publication date: August 27, 2020Inventors: Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
-
Patent number: 10690674Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.Type: GrantFiled: June 2, 2016Date of Patent: June 23, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Xi-Tao Wang, Olufemi A. Adelakun, Anne C. Lewin, Alan J. Korman, Mark J. Selby, Changyu Wang, Haichun Huang, Karla A. Henning, Nils Lonberg, Mohan Srinivasan, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Susan Chien-Szu Wong, Huiming Li
-
Publication number: 20200190180Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.Type: ApplicationFiled: December 27, 2019Publication date: June 18, 2020Inventors: Mohan SRINIVASAN, Shrikant DESHPANDE, Qihong ZHAO, Huadong SUN, Ginger RAKESTRAW, Guodong CHEN, Richard Y. HUANG, Steven SHERIFF, Cristian RODRIGUEZ, John P. THROUP, Rose A. DIBELLA
-
Patent number: 10683357Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: GrantFiled: March 30, 2017Date of Patent: June 16, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Zhehong Cai, Indrani Chakraborty, Marie-Michelle Navarro Garcia, Thomas D. Kempe, Alan J. Korman, Alexander T. Kozhich, Hadia Lemar, Mark Maurer, Christina Maria Milburn, Michael Quigley, Xiang Shao, Mohan Srinivasan, Kent Thudium, Susan Chien-Szu Wong, Jochem Gokemeijer, Xi-Tao Wang, Han Chang, Patrick Guirnalda
-
Patent number: 10653791Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.Type: GrantFiled: November 19, 2015Date of Patent: May 19, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Nils Lonberg, Alan J. Korman, Mark J. Selby, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Ming Lei, Liang Schweizer, Sandra V. Hatcher, Arvind Rajpal
-
Publication number: 20200138945Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: ApplicationFiled: October 11, 2019Publication date: May 7, 2020Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
-
Publication number: 20200115463Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: ApplicationFiled: October 25, 2019Publication date: April 16, 2020Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Guodong CHEN, Richard HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan WONG, Huiming LI